Evidence map›Paper›PMID 35629081›Full record

ArticleJournal of personalized medicine2022

Effectiveness of Statins for Primary Prevention of Cardiovascular Disease in Low- and Medium-Risk Males: A Causal Inference Approach with Observational Data.

Armando Chaure-Pardos, Isabel Aguilar-Palacio, Mª José Rabanaque, Mª Jesús Lallana, Lina Maldonado, Sara Castel-Feced, Julián Librero, José Antonio Casasnovas, Sara Malo

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Armando Chaure-PardosDirectorate of Public Health, Government of Aragón, 50017 Zaragoza, Spain.
Isabel Aguilar-PalacioInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0001-7293-701X
Mª José RabanaqueInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-6671-5661
Mª Jesús LallanaInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-3803-5298
Lina MaldonadoInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0003-1647-3462
Sara Castel-FecedInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-5064-3763
Julián LibreroUnidad de Metodología, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008 Pamplona, Spain.ORCID 0000-0002-4859-9054
José Antonio CasasnovasInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-9887-2629
Sara MaloInstituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-7194-8275

Funding

Instituto de Salud Carlos III PI17/01704
6 · The paper itself

Abstract

In this study, we analyzed the effectiveness of statin therapy for the primary prevention of cardiovascular disease (CVD) in low- and medium-risk patients. Using observational data, we estimated effectiveness by emulating a hypothetical randomized clinical trial comparing statin initiators with statin non-initiators. Two approaches were used to adjust for potential confounding factors: matching and inverse probability weighting in marginal structural models. The estimates of effectiveness were obtained by intention-to-treat and per-protocol analysis. The intention-to-treat analysis revealed an absolute risk reduction of 7.2 (95% confidence interval (CI95%), -6.6-21.0) events per 1000 subjects treated for 5 years in the matched design, and 2.2 (CI95%, -3.9-8.2) in the marginal structural model. The per-protocol analysis revealed an absolute risk reduction of 16.7 (CI95%, -3.0-36) events per 1000 subjects treated for 5 years in the matched design and 5.8 (CI95%, 0.3-11.4) in the marginal structural model. The indication for statin treatment for primary prevention in individuals with low and medium cardiovascular risk appears to be inefficient, but improves with better adherence and in subjectvs with higher risk.

Indexed as

cardiovascular diseasescomparative effectivenesshydroxymethylglutaryl-CoA reductase inhibitorsprevention and control

Identifiers

PMID35629081
PMCPMC9146525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.